AviadoBio

Latest news and press releases

AviadoBio Announces Presentation of Promising Preclinical Safety and Biodistribution Data of its Gene Therapy Candidate AVB-101 for FTD-GRN at the Annual European Society of Gene and Cell Therapy Congress

AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations

AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology

AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors

AviadoBio Appoints Graeme Fielder as Chief Operating Officer and Alex Bloom as Chief Technical Officer

AviadoBio selected by Fierce Biotech as a ‘Fierce 15’ 2022 winner

AviadoBio Appoints Dr. David Cooper as Chief Medical Officer

AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to Treatment of Frontotemporal Dementia

AviadoBio Announces Formation of Scientific Advisory Board

AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022

AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia

AviadoBio™ Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform

ABOUT US

Learn more about our mission to transform lives and our industry-leading team

SCIENCE & DELIVERY

Find out more about how we are progressing innovative gene therapies to potentially treat neurodegenerative disease. 

CAREERS

When you join AviadoBio, you join more than just a company, you join a dedicated team with a clear mission

 

CONTACT

We’d love to hear from you. If you have an enquiry about our gene therapies, delivery systems or clinical trials please contact us using the details here

en_USEnglish